Narrative ReviewEtiology & MechanismsClinical RelevanceDOI
3 min read
Jump to:

Patient-friendly summary

If you read nothing else

This review explores how hyaluronan in the fascia, affected by obesity, contributes to myofascial pain and potential treatments.

Bottom line

Hyaluronan's role in fascia is promising for treating obesity-related myofascial pain.

Preliminary evidence

How it works

  1. 1
    Hyaluronan changes
    In obesity, the amount and quality of hyaluronan in fascia can change, making it harder for fascial layers to slide over each other.
  2. 2
    Fascial sliding reduction
    When hyaluronan is altered, the fascia's ability to glide is reduced, leading to pain and stiffness.
  3. 3
    Inflammatory response
    Changes in hyaluronan can trigger inflammation, further worsening the pain and tissue health.

Words decoded

Fascia
— A layer of connective tissue that wraps around and separates muscles and other internal organs.
Myofascial disease
— A condition where the fascia and muscles don't work well together, causing pain and limited movement.
Hyaluronan
— A substance in the body that helps provide lubrication and structure in tissues like fascia.

Myth vs fact

Myth: Myofascial pain is just muscle pain.
Fact: Myofascial pain involves the fascia and its lubrication by hyaluronan, not just muscles.

Think of it like

Hyaluronan in fascia is like a lubricant between layers of a sandwich.

Just like mayonnaise helps the bread stick together and slide apart easily, hyaluronan lets the layers of fascia glide smoothly, reducing friction and pain.

Full research — for clinicians and curious readers

Study Summary

Background

Myofascial disease is a major cause of physical disability worldwide and a significant complication of obesity. With rising obesity rates, the burden of myofascial disorders is expected to worsen. Current treatment options are limited, creating an urgent need for new therapeutic strategies. This review examines how obesity affects the biochemical and mechanical properties of fascia, specifically focusing on hyaluronan, a key component of the fascial extracellular matrix.

What They Did

The authors conducted a comprehensive narrative review of existing literature on hyaluronan's role in fascial health and disease. They synthesized evidence from preclinical and clinical studies examining hyaluronan biochemistry, its function in healthy fascia, pathological changes in obesity, and therapeutic applications. The review integrates findings from molecular studies, animal models, and human clinical trials to build a comprehensive understanding of hyaluronan's role in obesity-related myofascial disease.

What They Found

Obesity creates a chronic inflammatory environment that disrupts hyaluronan homeostasis in multiple ways. The condition leads to increased production of low-molecular-weight hyaluronan fragments, which are pro-inflammatory, while reducing protective high-molecular-weight hyaluronan. Changes in adipose tissue metabolism, oxidative stress, and pH alterations affect hyaluronan's physical properties, reducing its lubricating function and increasing fascial stiffness. These changes contribute to fascial densification, where the normally smooth-gliding fascial layers become adherent and painful.

Clinical studies show promising results for hyaluronan injections in treating fasciopathies, with several trials demonstrating pain reduction and improved function comparable to or better than conventional treatments.

What This Means

This research reveals that hyaluronan dysfunction is a key mechanism linking obesity to myofascial pain, offering new therapeutic targets. Understanding how obesity alters fascial biochemistry helps explain why obese patients are more prone to myofascial disorders. The review supports hyaluronan supplementation as a rational treatment approach, given its unique properties of biocompatibility, minimal side effects, and ability to restore normal fascial mechanics. For clinicians, this suggests that hyaluronan injections could be valuable for obese patients with myofascial pain who haven't responded to conventional treatments.

Future research should focus on optimizing molecular weight, dosing protocols, and identifying which patients benefit most from this approach.

70/100
Evidence StrengthModerate
Study Quality
Sample Size
Replication
13%
Global Obesity Prevalence
85%
People Experience Myofascial Pain
15g
Total Body Hyaluronan

Key Findings

Obesity increases low-molecular-weight hyaluronan fragmentsHigh

These fragments are pro-inflammatory and contribute to fascial dysfunction through TLR-mediated immune activation

Fascial densification occurs when hyaluronan changes from lubricating to adhesiveHigh

This process reduces tissue sliding capacity and increases stiffness, contributing to myofascial pain

Hyaluronan injections show clinical efficacy in fasciopathiesHigh

Multiple studies demonstrate pain reduction and functional improvement comparable to conventional treatments

Obesity creates chronic inflammation affecting hyaluronan homeostasisMedium

Adipose tissue inflammation disrupts normal hyaluronan synthesis and degradation pathways

Physical properties of hyaluronan are altered by obesity-related factorsMedium

Temperature changes, pH alterations, and oxidative stress modify hyaluronan's biomechanical properties

Study Methodology
Study Design
Narrative review of literature
Sample Size
Multiple studies reviewed
Duration
Comprehensive analysis of existing research
Population
Obesity and myofascial pain research
Outcome Measures
Biochemical analysis · Clinical outcomes · Pathophysiological mechanisms

Strengths

  • Comprehensive synthesis of current knowledge on hyaluronan and obesity
  • Integrates molecular mechanisms with clinical applications
  • Well-structured analysis from biochemistry to therapeutics
  • Identifies specific pathophysiological pathways linking obesity to myofascial disease

Limitations

  • Narrative review format limits systematic evidence assessment
  • Limited direct evidence specifically in obese populations with myofascial disease
  • Calls for more rigorous clinical trials to validate therapeutic potential
  • Lacks quantitative meta-analysis of treatment outcomes

Key Takeaways for Patients

What This Means for You

  1. 01Obesity increases your risk of developing chronic muscle and joint pain through effects on connective tissue
  2. 02The body's natural lubricating substances become damaged in obesity, leading to tissue stiffness and pain
  3. 03New treatments using hyaluronic acid injections may help restore normal tissue function
  4. 04Maintaining healthy weight may help prevent fascial problems and associated pain
  5. 05These insights may lead to better targeted treatments for obesity-related pain conditions

Read the Full Paper

Access the complete peer-reviewed study from International Journal of Molecular Sciences

View Full Study

Related Research

●●●●● LandmarkNarrative Review

Myofascial Trigger Points Then and Now: A Historical and Scientific Perspective

Shah et al.·PM R·2015

This narrative review traces the evolution of myofascial trigger point understanding from 19th-century clinical observations through modern biochemical, imaging, and neurophysiological research, revealing emerging objective evidence for a condition long diagnosed by palpation alone.

Etiology & MechanismsRead →
●●●●● LandmarkNarrative Review

A Brief Overview and Update of Myofascial Pain Syndrome and Myofascial Trigger Points

Gerber et al.·Journal of The Spinal Research Foundation·2011

This comprehensive review examines the pathophysiology of myofascial trigger points, revealing elevated inflammatory markers and altered tissue properties. The research provides objective evidence supporting trigger point diagnosis using ultrasound imaging and validates treatment mechanisms.

Etiology & MechanismsRead →
●●●●● LandmarkLaboratory Study

Hyaluronan within fascia in the etiology of myofascial pain

Stecco et al.·Surgical and Radiologic Anatomy·2011

Study reveals hyaluronan as a key lubricant in fascial layers and proposes that alterations in this sliding mechanism may be the underlying cause of myofascial pain. Discovery of specialized "fasciacyte" cells suggests new targets for treatment.

Etiology & MechanismsRead →
●●●●● LandmarkNarrative Review

Myofascial trigger points: spontaneous electrical activity and its consequences for pain induction and propagation

Ge et al.·Chinese Medicine·2011

This review reveals that spontaneous electrical activity at myofascial trigger points represents sustained muscle contractions that create local ischemia and pain sensitization. Active trigger points can transition localized pain to generalized pain conditions through central nervous system sensitization.

Etiology & MechanismsRead →